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Abstract
Background Chronic obstructive pulmonary disease
(COPD) patients with blood eosinophil (EOS) count C2 %
benefit from exacerbation reductions with inhaled corti-
costeroids (ICSs). We conducted post hoc analyses to
determine if EOS count C2 % is a marker for greater
responsiveness to the bronchodilators umeclidinium
(UMEC; long-acting muscarinic antagonist), vilanterol
(VI; long-acting b2-agonist) or UMEC/VI combination.
Methods Effects of once-daily UMEC/VI 62.5/25,
UMEC 62.5 and VI 25 lg versus placebo on trough forced
expiratory volume in one second (FEV1), Transition
Dyspnoea Index (TDI), St George’s Respiratory Ques-
tionnaire (SGRQ) scores and adverse event (AE) inci-
dences in four completed, 6-month studies were assessed
by EOS subgroup. Trough FEV1 was also evaluated by ICS
use and EOS subgroup. Analyses were performed using a
repeated measures model.
Results At baseline, 2437 of 4647 (52 %) patients had
EOS count C2 %. Overall, &50 % of patients used ICSs.
At day 169, no notable variations were observed in trough
FEV1 least squares mean differences between EOS sub-
groups versus placebo for UMEC/VI, UMEC and VI;
results according to ICS use were similar. No differences
were reported between EOS subgroups in TDI and SGRQ
scores on day 168, or for incidences of AEs, serious AEs
and AEs leading to withdrawal.
Conclusions Response to UMEC/VI, UMEC and VI in
terms of trough FEV1, dyspnoea and health-related quality
of life was similar for COPD patients with baseline EOS
counts C2 or\2 %. EOS count did not appear to predict
bronchodilator response in either ICS users or non-users.
Key Points
Response, as assessed by trough forced expiratory
volume in 1 s, dyspnoea and health-related quality of
life, to treatment with once-daily umeclidinium
(UMEC)/vilanterol (VI) (62.5/25 lg), UMEC
(62.5 lg) or VI (25 lg) was similar in chronic
obstructive pulmonary disease patients with
eosinophil (EOS) counts\2 or C2 % at baseline.
EOS count does not appear to predict bronchodilator
response in either inhaled corticosteroid users or
non-users.
No notable differences were observed between EOS
subgroups in the incidence of adverse events (AEs),
serious AEs or AEs leading to withdrawal
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1 Introduction
Eosinophilic airway inflammation, which can increase
during exacerbations, occurs in some patients with chronic
obstructive pulmonary disease (COPD) [1]. It has been
suggested that a biomarker for such inflammation is blood
eosinophil (EOS) count [2] and that an EOS count of C2 %
may be associated with an increased COPD exacerbation
risk [3]. This EOS cut-off may identify patients who would
benefit from exacerbation reduction with inhaled corticos-
teroids (ICSs) [4, 5]. Pascoe et al. [5] investigated different
EOS cut-offs and found 2 % to be the most appropriate.
A question of interest is whether a blood EOS count of
C2 % is a marker of patients who are responsive not only
to ICSs but also to bronchodilators. We conducted post hoc
analyses to determine if EOS count C2 % is a marker for
greater responsiveness to bronchodilator treatment with
umeclidinium [UMEC; long-acting muscarinic antagonist
(LAMA)], vilanterol [VI; long-acting b2 agonist (LABA)]
and UMEC/VI.
2 Methods
Details of the four 24-week, multicentre, randomised,
placebo- or active-controlled studies are published (Clini-
caltrials.gov identifiers: NCT01313637, NCT01313650,
NCT01316900, NCT01316913) [6–8]. Key inclusion cri-
teria were males and females (C40 years) with COPD;
current or former cigarette smokers (C10 pack-year
smoking history); post-salbutamol forced expiratory vol-
ume in 1 s (FEV1)/forced vital capacity\0.7 and predicted
FEV1 B70 % of normal; and a modified Medical Research
Council dyspnoea score C2 [6–8].
In study NCT01313637,1 1493 patients were ran-
domised 3:3:3:2 to UMEC/VI 125/25 (delivering
113/22 lg), UMEC 125, VI 25 lg or placebo, respectively
[6]. In study NCT01313650, 1532 patients were ran-
domised 3:3:3:2 to UMEC/VI 62.5/25 lg (delivering
55/22 lg), UMEC 62.5, VI 25 lg or placebo, respectively
[7]. In studies NCT01316900 and NCT01316913, 2332
patients were randomized 1:1:1:1 to UMEC/VI 125/25,
UMEC/VI 62.5/25 lg, tiotropium bromide 18 lg, and
either VI 25 or UMEC 125 lg, respectively [8]. Once-
daily treatments were administered using the ELLIPTA
dry powder inhaler2 except for tiotropium (administered
via the Handihaler).
Post hoc subgroup analyses used integrated data
(n = 4713) from the intent-to-treat (ITT) populations in
these studies, excluding one site due to Good Clinical
Practice (GCP) violations. Subgroups were defined by EOS
category (\2 or C2 %) at baseline. As patients could take a
concurrent stable dose of an ICS throughout these studies,
additional subgroups were defined according to ICS use at
screening and baseline EOS category. Trough FEV1 (pri-
mary efficacy endpoint in each study), Transition Dysp-
noea Index (TDI) focal score and St George’s Respiratory
Questionnaire (SGRQ) total score were analysed using a
repeated measures model [terms: study, treatment, smoking
status at screening, baseline or Baseline Dyspnea Index
(BDI), day, geographical region, EOS subgroup, and day
by baseline/BDI, day by treatment, EOS subgroup by
treatment, and EOS subgroup by day by treatment inter-
actions]. Trough FEV1 was also analysed by additional
EOS subgroups of\4 or C4,\6 or C6, and\2 %, 2 to\4,
4 to\6 or C6 % (using the same model), and by EOS
category and ICS use, using the same model but using the
4-level ICS/EOS subgroup instead of EOS subgroup.
Adverse events (AEs), serious AEs (SAEs) and AEs
leading to withdrawal were summarised by EOS category.
Data are presented for UMEC/VI 62.5/25 and UMEC
62.5 lg (both approved doses), and VI 25 lg.
3 Results
At baseline, 2210 of 4647 (48 %) and 2437 of 4647 (52 %)
patients had EOS counts \2 and C2 %, respectively.
Across treatments, the proportion of patients with EOS
count C2 % was similar (49–55 %). Approximately 50 %
of all patients were ICS users. The overall proportion of
patients with EOS C2 % was 53 % (47–61 % across
treatments) for ICS users, and 52 % (49–53 %) for non-
ICS users.
For the overall ITT populations, patient demographics
and disease characteristics (Electronic Supplementary
Material Table S1) for each treatment (data not shown)
were well matched between EOS subgroups.
In the EOS\2 and C2 % subgroups, trough FEV1 was
statistically significantly increased by UMEC/VI, UMEC
and VI versus placebo at all timepoints (p\ 0.001;
Fig. 1a–c). There were no differences between the EOS\2
and C2 % subgroups in trough FEV1 least squares (LS)
mean differences from placebo for UMEC/VI, UMEC and
VI treatments (Fig. 1a–c). The LS mean differences (95 %
confidence interval) from placebo for EOS \2 versus
C2 %, respectively, at day 169 were 197 (155–238) versus
205 mL (166–245) with UMEC/VI; 139 (89–189) versus
130 mL (83–176) with UMEC; and 109 (69–150) versus
100 mL (62–138) with VI. Results for EOS subgroups
using different cut-offs were very similar to those using the
2 % cut-off (data not shown). The trough FEV1 results with
1 The doses of UMEC used in this study (UMEC/VI 125/25 lg,
UMEC 125 lg) are not approved.
2 ELLIPTA is a trademark of the GSK group of companies.
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UMEC and VI in patients with baseline EOS counts\2 or
C2 % were more variable in ICS users and non-users than
in the overall population (Fig. 1d–f).
There were no differences in the LS mean difference
from placebo in TDI focal score or SGRQ total score
between EOS \2 and C2 % subgroups for UMEC/VI,
UMEC and VI treatments at day 168 (Electronic Supple-
mentary Material Table S2), or at any other timepoints
evaluated (data not shown).
For the EOS\2 and C2 % subgroups, respectively, the
incidences of AEs were 49–56 and 46–55 %, SAEs were
3–7 and 4–7 %, and AEs leading to withdrawal were 4–8
and 4–7 % across treatment groups.
4 Discussion
Our retrospective analyses of a large dataset demonstrate
that the response [assessed by trough FEV1, dyspnoea and
health-related quality of life (HR-QOL)] to treatment with
once-daily UMEC/VI (62.5/25 lg), UMEC (62.5 lg) or VI
(25 lg) was similar in COPD patients with EOS counts\2
or C2 % at baseline. In addition, the EOS count does not
appear to predict bronchodilator response in either ICS
users or non-users. Moreover, no remarkable differences in
the incidence of AEs, SAEs or AEs leading to withdrawal
were observed between EOS subgroups.
Our findings with UMEC and VI are in contrast to
results with corticosteroids in COPD patients. For example,
an EOS cut-off of C2 % was identified as a potential
biomarker to guide whether oral corticosteroid therapy was
required to prevent COPD exacerbations [4]. With the ICS/
LABA combination of fluticasone furoate/VI, COPD
exacerbations were significantly reduced by 29 %
(p\ 0.001) in the EOS count C2 % subgroup, but only by
10 % (p = 0.283) in the EOS count\2 % subgroup [5].
This is supported by the randomised, double-blind, paral-
lel-group FORWARD (FOsteR 48-week trial to reduce
exAceRbations in COPD) study, which reported that
increasing blood EOS count was associated with a greater
reduction in exacerbations when beclomethasone dipropi-
onate was added to formoterol fumarate in patients with
severe COPD and a history of exacerbations [9]. This
differential response is perhaps unsurprising given that
corticosteroids act as anti-inflammatory agents in COPD
and EOS are a corticosteroid-responsive cell type [10],
while, in contrast, LABAs and LAMAs act as bron-
chodilators via stimulation of adrenergic receptors or
inhibition of muscarinic receptors, respectively [11],
although LAMAs have some anti-inflammatory properties
[12]. Biomarkers have great potential to improve decision
making in COPD. Our results suggest that EOS will not be
of value in making decisions about bronchodilator use;
however, these findings need to be confirmed in prospec-
tive studies.
5 Conclusion
Response to UMEC/VI, UMEC and VI in terms of trough
FEV1, dyspnoea and HR-QOL was similar for COPD
patients with EOS counts C2 or\2 % at baseline. EOS
a b c
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Fig. 1 Least squares mean differences from placebo in trough force
expiratory volume at 1 s (at various timepoints) with umeclidinium/
vilanterol, umeclidinium and vilanterol treatment, by baseline
eosinophil subgroup (a–c), and by baseline eosinophil subgroup and
concomitant inhaled corticosteroid use (d–f). CI confidence interval,
EOS eosinophil, ICS inhaled corticosteroid, LS least squares, UMEC
umeclidinium, VI vilanterol
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count did not appear to predict bronchodilator response in
either ICS users or non-users.
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